A retrospective, multicenter study of use of neoadjuvant vismodegib in locally advanced periocular basal cell cancer patients
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Nov 2021 New trial record
- 01 Oct 2021 Results published in the Eye